Boulder-based Biodesix raises another $5.1 million
BOULDER — Local diagnostic test-maker Biodesix Inc. has pulled in another new chunk of funding as the company continues to grow its Veristrat and other products.
According to a regulatory filing made this week, the company has raised about $5.1 million through the issuance of new convertible notes. The filing noted a total offering of $15.7 million, meaning more cash could be on the way.
Biodesix CEO David Brunel couldn’t be reached for comment Friday.
SPONSORED CONTENT
The many benefits of simple, coordinated healthcare
Kaiser Permanente combines health care and coverage in one connected system to maximize employee health and minimize employer costs.
Biodesix, which is headquartered at 2970 Wilderness Place, makes a line of blood tests that are focused on identifying which cancer patients could best benefit from various cancer drugs, because most cancer drugs work only on specific sets of the population.
In February, the company raised a Series F funding round of $17.8 million, and then tacked on another $6.1 million of equity funding in July. The company has now raised well more than $100 million since its founding in 2005.
BOULDER — Local diagnostic test-maker Biodesix Inc. has pulled in another new chunk of funding as the company continues to grow its Veristrat and other products.
According to a regulatory filing made this week, the company has raised about $5.1 million through the issuance of new convertible notes. The filing noted a total offering of $15.7 million, meaning more cash could be on the way.
Biodesix CEO David Brunel couldn’t be reached for comment Friday.
Biodesix, which is headquartered at 2970 Wilderness Place, makes a line of blood tests that are focused on identifying which…
THIS ARTICLE IS FOR SUBSCRIBERS ONLY
Continue reading for less than $3 per week!
Get a month of award-winning local business news, trends and insights
Access award-winning content today!